Abstract
Since its outbreak in late 2019, the SARS-Cov-2 pandemic already infected over 3.7 million people and claimed more than 250,000 lives globally. At least 1 year may take for an approved vaccine to be in place, and meanwhile millions more could be infected, some with fatal outcome. Over thousand clinical trials with COVID-19 patients are already listed in ClinicalTrials.com, some of them for assessing the utility of therapeutics approved for other conditions. However, clinical trials take many months, and are typically done with small cohorts. A much faster and by far more efficient method for rapidly identifying approved therapeutics that can be repurposed for treating COVID-19 patients is data mining their past and current electronic health and prescription records for identifying drugs that may protect infected individuals from severe COVID-19 symptoms. Examples are discussed for applying health and prescription records for assessing the potential repurposing (repositioning) of angiotensin receptor blockers, estradiol, or antiandrogens for reducing COVID-19 morbidity and fatalities. Data mining of prescription records of COVID-19 patients will not cancel the need for conducting controlled clinical trials, but could substantially assist in trial design, drug choice, inclusion and exclusion criteria, and prioritization. This approach requires a strong commitment of health provides for open collaboration with the biomedical research community, as health provides are typically the sole owners of retrospective drug prescription records.
Keywords: COVID-19; TMPRSS2; drug repositioning; drug repurposing; electronic health records (EHR).
【저자키워드】 COVID-19, Drug repurposing, TMPRSS2, drug repositioning, electronic health records (EHR)., 【초록키워드】 TMPRSS2, Vaccine, clinical trial, pandemic, Trial, Therapeutics, SARS-CoV-2 pandemic, clinical trials, drug, outcome, Angiotensin receptor blockers, Electronic health record, Health, outbreak, morbidity, Patient, estradiol, Community, utility, COVID-19 patients, retrospective, angiotensin, Electronic health records, COVID-19 patient, Biomedical research, EHR, criteria, exclusion criteria, open, other conditions, Receptor Blockers, infected individual, infected individuals, controlled clinical trials, cohorts, exclusion, over, severe COVID-19 symptoms, Inclusion, approach, PROTECT, approved, provide, faster, reducing, conditions, assist, claimed, treating COVID-19 patient, with COVID-19, 【제목키워드】 repurposing,